- India
- /
- Life Sciences
- /
- NSEI:INNOVACAP
Innova Captab Full Year 2025 Earnings: Revenues Disappoint
Innova Captab (NSE:INNOVACAP) Full Year 2025 Results
Key Financial Results
- Revenue: ₹12.4b (up 15% from FY 2024).
- Net income: ₹1.28b (up 36% from FY 2024).
- Profit margin: 10% (up from 8.7% in FY 2024). The increase in margin was driven by higher revenue.
- EPS: ₹22.41 (up from ₹18.66 in FY 2024).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Innova Captab Revenues Disappoint
Revenue missed analyst estimates by 1.5%. Earnings per share (EPS) was mostly in line with analyst estimates.
Looking ahead, revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Life Sciences industry in India.
Performance of the Indian Life Sciences industry.
The company's shares are up 2.1% from a week ago.
Risk Analysis
We should say that we've discovered 1 warning sign for Innova Captab that you should be aware of before investing here.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NSEI:INNOVACAP
Innova Captab
An integrated pharmaceutical company, engages in the research and development, manufacture, distribution, and marketing of drugs in India and internationally.
High growth potential with excellent balance sheet.
Similar Companies
Market Insights
Weekly Picks

Is this the AI replacing marketing professionals?

GameStop will ace the financial crisis wave with its strategic Bitcoin investment and cash reserves

An Undervalued 3.3Moz Gold Project in Canada
The First Real Lidar Winner
Recently Updated Narratives

50% ROE in a Burning Building
NVIDIA will see a profit margin surge of 55% in the next 5 years

Near zero debt, Japan centric focus provides future growth
Popular Narratives
SoFi Technologies: The Apex Aggregator and the Infrastructure of the Modern Financial System

Everyone's Terrified Microsoft Will Keep Spending. I'm Terrified They'll Stop.

